Influence of Prognostic Factors on Overall Survival in Myelodysplastic Syndromes

Sotirova, Tatjana; Stojanović, Aleksandar; Genadieva-Stavric, Sonja; Krstevska, Svetlana; Spasovski, Dejan; Balkanov, Trajan

doi:10.5455/msm.2014.26.292-296

Cited by 7 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, type B studies reported improved 2 year OS in TI patients (51.8% vs 22.5%, P < .0001) 18 ; median OS was longer in patients who achieved TI ≥8 weeks (4.3 years; 95% CI: 3.6‐5.9) than in non‐responders (2.0 years; 95% CI: 1.3‐2.2; P < .0001) 22 . Of the type C studies, no significant difference in OS was observed between patients with a high transfusion burden compared to patients who required ≤18 units of RBC over a period of 3 years of follow‐up ( P = .72185) 23 …”

Section: Resultsmentioning

confidence: 92%

“…After applying the inclusion/exclusion criteria, 75 studies were excluded for containing outcomes other than OS, and 16 studies excluded due to lack of required results. The final list included ten studies for qualitative analysis: six published articles 18‐23 and four abstracts 24‐27 (Figure 1). These ten studies were added to the list of studies included by Harnan et al (2016; 12 studies) 15,28‐39 .…”

Section: Resultsmentioning

confidence: 99%

“…These ten studies were added to the list of studies included by Harnan et al (2016; 12 studies) 15,28‐39 . The total 22 studies included in the SLR are listed in Table 3 18‐39 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis

Lemos

Rodrigues

Schroeder

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are a group of malignant hematologic diseases characterized by ineffective hematopoiesis, which may lead to chronic anemia and transfusion dependency, with up to 30% of patients progressing to acute myeloid leukemia (AML). Studies suggest transfusion dependency may impact overall survival (OS); however, there is a lack of evidence concerning the association between transfusion status (TS) and OS in patients with MDS who become transfusion independent (TI) after treatment. In addition, the holistic impact of TS on other clinical, economic, and humanistic outcomes has not been well understood. We conducted a systematic literature review (SLR) to understand this impact. Ten studies were included and showed consistent decrease in OS in transfusion dependent (TD) compared with TI patients. These findings were confirmed by a meta‐analysis (MA) reporting better OS prognosis for TI patients. A second SLR was conducted to understand the association between TS and other clinical, economic, and humanistic outcomes. Twenty‐eight studies were included and showed better prognosis for other outcomes, including AML progression and leukemia‐free survival for TI patients. Risk of AML progression and cumulative non‐leukemic death assessed by the MA showed a trend toward worse prognosis and higher risk of AML progression for TD patients. Lower healthcare resource utilization, better quality of life, and reduced non‐leukemic death for TI patients were observed. Studies not eligible for MA also showed better clinical, economic, and humanistic outcomes for TI patients. These findings contribute to understanding the association between transfusion dependence and OS among other outcomes in patients with MDS.

show abstract

Section: Resultsmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis

Lemos

Rodrigues

Schroeder

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…18 In another study by Sotirova et al, patients with ferritin <500 µg/L were shown to have better OS. 19 Kikuchi et al found that serum ferritin levels of higher risk MDS patients were significantly higher than lower risk patients. Interestingly, ferritin levels of MDS patients with chromosomal abnormality were significantly higher than patients with normal karyotype.…”

Section: Figurementioning

confidence: 99%

Ferritin: Is it a Predictor of Prognosis in Myelodysplastic Syndrome?

Yeğin¹,

Hızal²,

Sadioğlu³

et al. 2017

World Clin J Med Sci

View full text Add to dashboard Cite

“…2,3 Various prognostic indicators used in previous studies in myelodysplastic syndrome include clinical factors like age, gender, comorbidities and laboratory variables like haemoglobin levels, serum albumin, red cell distribution width, mean corpuscular volume, serum ferritin and lactate dehydrogenase. 4,5,6,7,8,9 Multiple studies from the west have shown serum albumin levels at presentation to correlate well with prognosis of patients. 4,10,11,12,13 Studies from India investigating the levels of serum albumin with prognosis of patients with myelodysplastic syndrome are scanty.…”

mentioning

confidence: 99%

A Study of the Prognostic Significance of Serum Albumin Levels in Myelodysplastic Syndrome

Malayath¹

2019

jebmh

View full text Add to dashboard Cite

BACKGROUND Myelodysplastic syndromes are clonal marrow stem cell disorders characterised by ineffective haemopoiesis leading to blood cytopenias. Various prognostic parameters have been used to assess the prognosis of the disease like age, gender, IPSS score, modified IPSS score, serum albumin, Red Cell Distribution Width (RDW), serum ferritin and Lactate Dehydrogenase (LDH). Multiple studies from the west have shown serum albumin levels at presentation to correlate well with prognosis of patients. Studies from India investigating the levels of serum albumin with prognosis of patients with myelodysplastic syndrome are scanty. The aim of this study was to investigate the relationship of serum albumin levels at presentation of patients and the consequent development of complications and death that occurred in the follow-up period of patients with myelodysplastic syndrome. METHODS For this purpose, we studied 117 consecutive confirmed cases of myelodysplastic syndrome that presented to the Department of Medicine and Haematology in Calicut Government Medical College between July 2009 and June 2013. Serum albumin levels were taken on diagnosis. All patients were followed up till December 2014 and subsequently developing complications both outpatient and inpatient) along with deaths that occurred were studied. RESULTS Although, only 40.2% of patients with myelodysplastic syndrome had low serum albumin at presentation, the undifferentiated subtype, RAEB-2 subtype and RAEB-1 had a statistically significant low serum albumin levels. Of the 47 patients who had low serum albumin, 33 patients had developed complications during the course of the illness. Of the 70 patients who had normal serum albumin, 35 had developed complications, which was statistically significant. CONCLUSIONS A low level of serum albumin (<3.5 mg%) at presentation in cases of myelodysplastic syndrome was statistically associated with poor prognostic subtypes of myelodysplastic syndrome and in turn was associated with high levels of complications and mortality during the course of illness.

show abstract

Influence of Prognostic Factors on Overall Survival in Myelodysplastic Syndromes

Cited by 7 publications

References 34 publications

Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis

Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis

Ferritin: Is it a Predictor of Prognosis in Myelodysplastic Syndrome?

A Study of the Prognostic Significance of Serum Albumin Levels in Myelodysplastic Syndrome

Contact Info

Product

Resources

About